comparing therapy benefit from initially her2 positive or negative metastatic breast cancer patients
Published 3 years ago • 1.5K plays • Length 4:53Download video MP4
Download video MP3
Similar videos
-
3:08
the molecular differences between younger versus older er-positive and her2-negative breast cancers
-
1:25
current state of cdk4/6 inhibitors in metastatic her2-negative breast cancer
-
5:37
therapeutic landscape for patients with her2-positive breast cancer with active brain metastases
-
2:24
identifying drivers of first-line hr /her2- metastatic breast cancer treatment choices
-
4:12
optimizing treatment in patients with early-stage her2-positive breast cancer
-
1:42
her2dx and pcr in her2-positive breast cancer: a combined analysis of 4 neoadjuvant studies
-
7:30
#esmo21 expert video report on her2-positive metastatic breast cancer
-
3:05
pi3k inhibitors for the treatment of brain metastases in her2-negative breast cancer
-
8:49
case study: treating her2-positive metastatic breast cancer, part i
-
1:29
poziotinib for her2-positive metastatic breast cancer
-
3:30
final results from pallas: adjuvant palbociclib in hr /her2- early breast cancer
-
3:32
sequencing novel her2-targeted therapies in metastatic breast cancer
-
5:01
cdk4/6 inhibitors: sequencing endocrine therapy for metastatic breast cancer
-
7:27
polaris: palbociclib for bipoc patients with her2-negative breast cancer
-
4:46
entinostat, nivolumab and ipilimumab in advanced her2-negative breast cancer
-
55:48
new & supporting data for optimizing therapy in her2 breast cancer | dr. bagegni & dr. gradishar
-
0:35
key challenge associated with the management of hr /her2- breast cancer
-
3:44
alternate: neoadjuvant endocrine treatment in er /her2- breast cancer
-
1:02
combination therapies incorporating adcs in breast cancer